Modi Ventures

Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method and contribute to advancements in technology and innovation.

Ignota Labs is a medical technology company focused on enhancing the drug discovery process by utilizing advanced artificial intelligence methods, including deep learning and machine learning. The company's platform aims to optimize the identification of toxic compounds, which can lead to costly delays and safety errors in bringing new medications to market. By predicting toxic endpoints early in the development process, Ignota Labs not only improves drug safety but also promotes sustainability within the pharmaceutical industry by minimizing environmental harm and waste associated with harmful compounds.

Innotap is a prominent provider of energy trading and commodity trading software, specializing in real-time decision support applications for power traders. The company offers a suite of tools, including DecisionDock®, InstaTrend®, RealDeal® Dashboards, and PowerFeed® for Excel®, designed to help clients monitor market events and make informed trading decisions. By delivering cloud-based software and aggregating data from Independent System Operators (ISOs) and Regional Transmission Organizations (RTOs), Innotap enables energy traders to seize opportunities swiftly in a dynamic market. Its solutions feature advanced data visualization and analytics capabilities, streamlining real-time market data integration into spreadsheets, which enhances the decision-making process for traders.

Lapsi Health is a technology company based in Amsterdam, established in January 2022, that specializes in developing sound-based biomarkers for clinical medicine. The company focuses on innovative technologies that utilize audio and photo-sensor data to enhance the screening and monitoring of various diseases. By improving data usage in healthcare, Lapsi Health aims to contribute to the diagnosis and treatment of a wide range of disorders, ultimately advancing the capabilities of medical practice.

General Proximity is an innovative biotech company focused on the development of next-generation induced-proximity medicines. The company aims to enhance future medical treatments by activating existing cellular machinery to address harmful human diseases. Through its pioneering approach to proximity medicine, General Proximity envisions a transformative impact on healthcare, enabling doctors to deliver more effective therapies for patients.

March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. The company's lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 1 trials in patients with refractory T-cell lymphoma and leukemia.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

PathPresenter is a global image-sharing platform focused on pathology, aiming to enhance access to pathology knowledge by facilitating the sharing of image data, artificial intelligence algorithms, and professional expertise. The platform offers a secure and HIPAA-compliant environment that connects pathologists worldwide, allowing them to collaborate more effectively. By fostering this exchange of medical images and insights, PathPresenter seeks to improve patient care and support the professional development of pathologists.

Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Tiny Health is a prominent microbiome health platform focused on improving health outcomes for individuals dealing with chronic conditions and those seeking to enhance their overall wellness. The company offers the first at-home gut microbiome test specifically designed for pregnant mothers and their babies, utilizing advanced shotgun metagenomics. In addition to these tests, Tiny Health provides microbiome assessments for older children and adults, as well as vaginal health tests. More than 30,000 families have relied on Tiny Health to address imbalances in their gut and vaginal microbiomes, utilizing personalized dietary, supplement, and lifestyle recommendations based on test results. This evidence-based approach has helped many individuals alleviate severe symptoms and, in some cases, reverse chronic conditions. Tiny Health's team comprises leading scientists, physicians, and microbiologists from prestigious institutions, ensuring a strong foundation in research and clinical expertise.

Harbinger Health is a biotechnology company focused on the early detection of cancer through a two-tier blood testing model. By integrating artificial intelligence and machine learning, the company aims to identify cancer at its earliest stages, even before symptoms become apparent. This innovative approach seeks to provide low-cost, multi-cancer blood tests that enhance diagnostic capabilities for healthcare professionals, ultimately facilitating more timely and effective interventions for patients.

Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets. Unnatural Products was founded in 2017 and is headquartered in Santa Cruz, California.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Atomic AI is focused on advancing RNA drug discovery through the integration of machine learning and structural biology. The company operates a content intelligence platform that facilitates the rational design of new molecules and medicines. By leveraging engagement data from clients' analytics, Atomic AI gathers insights to create predictive reports on various topics, including optimal publishing times and distribution channels. This approach equips users with innovative strategies to develop treatments or cures for diseases by specifically targeting RNA structures.

Perceptive is focused on the design, development, and manufacturing of medical devices specifically for the dentistry sector. The company has pioneered automated robotics technology that aims to revolutionize dental care by establishing image-guided robotic restorative dentistry as a standard practice. This innovative technology enhances the precision with which dentists can identify and eliminate tooth decay, ultimately delivering superior restorations to patients more efficiently and at a reduced cost. By leveraging advanced techniques, Perceptive enhances clinical capacity and aims to improve overall dental care practices.

Flawless is a company that has developed TrueSync, the first system that utilizes artificial intelligence to create precisely lip-synced visualizations in multiple languages. This innovative platform focuses on preserving the nuances and emotional depth of the original content, addressing common issues found in traditional dubbing and subtitling, which often alter scripts and disrupt synchronization. By maintaining the quality and immersion of the original material, Flawless enhances the viewing experience and broadens the potential audience for films and shows. Their technology enables filmmakers to deliver content in various languages while ensuring that the performances of actors remain authentic and true to the original, ultimately increasing the value of the material for international markets.

Ashvattha Therapeutics, Inc. is a biotechnology company focused on developing pharmaceutical products that address unmet medical needs in neurology, oncology, and ophthalmology, as well as inflammatory diseases. Founded in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company specializes in hydroxyl dendrimer therapeutics. These innovative therapies are designed to selectively target actively endocytosing cells, such as reactive microglia and macrophages, which play significant roles in chronic inflammation and disease progression. By improving precision targeting, Ashvattha aims to minimize off-target toxicity, systemic side effects, and immunogenicity commonly associated with other therapeutic platforms. The company currently has a pipeline of nine therapeutics under development, focusing on enhancing treatment efficacy while reducing adverse effects for patients.

Lapsi Health is a technology company based in Amsterdam, established in January 2022, that specializes in developing sound-based biomarkers for clinical medicine. The company focuses on innovative technologies that utilize audio and photo-sensor data to enhance the screening and monitoring of various diseases. By improving data usage in healthcare, Lapsi Health aims to contribute to the diagnosis and treatment of a wide range of disorders, ultimately advancing the capabilities of medical practice.

Starling Medical focuses on creating a remote patient monitoring platform that facilitates at-home urine diagnostics, integrating seamlessly into everyday bathroom routines. The company is developing a healthcare device that employs mass spectroscopy-based sensors to continuously monitor changes in urine composition. This technology aims to enable early detection of chronic health issues, allowing both patients and healthcare providers to intervene promptly and potentially prevent serious complications or hospitalizations. By offering predictive insights, Starling Medical aspires to enhance health outcomes through proactive monitoring.